Boehringer Ingelheim Pharmaceuticals, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$109Mgeneral payments (2019-2025)
$4.7Mresearch payments (2019-2025)
190,065clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Jardiance $22M associated (2023-2025)
- Ofev $5.0M associated (2023-2025)
- Spevigo $2.9M associated (2023-2025)
- Synjardy $593K associated (2023-2025)
- Tradjenta $437K associated (2023-2025)
- Stiolto Respimat $351K associated (2023-2025)
- Spiriva Respimat $299K associated (2023-2025)
- Cyltezo $295K associated (2023-2025)
- Gilotrif $159K associated (2023-2025)
- Jascayd $131K associated (2023-2025)
- Pradaxa $58K associated (2023-2025)
- Glyxambi $31K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Russell Carlisle | Wesson, MS | Family Medicine | $1,568,605.91 |
| Robert Lorence | Bethesda, MD | $1,229,215.20 | |
| Anthony De Padova | Basking Ridge, NJ | $899,254.50 | |
| Harry Ulrich | Bronx, NY | $826,901.92 | |
| William Bowen | Saint Louis, MO | Cardiovascular Disease | $723,814.11 |
| Steven Nathan | Falls Church, VA | Pulmonary Disease | $655,431.23 |
| Virginia Shawver | Plantation, FL | $610,737.78 | |
| Ayodeji Adegunsoye | Chicago, IL | Pulmonary Disease | $457,533.36 |
| Robert Suh | Los Angeles, CA | Diagnostic Radiology | $389,778.57 |
| Joseph Mammarappallil | Durham, NC | Diagnostic Radiology | $366,511.30 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.